X
GO

Dr. Michele Carbone's Scientific Publications

Oncogene - Meeting Report:

Oncogene - Meeting Report:

Association of SV40 with human tumors

Meeting Report:   Studies conducted by the various investigators were presented addressing the association of SV40 with human mesothelioma. Joseph Testa (Fox Chase Cancer Center, Philadelphia, PA, USA) reported the conclusions of a multi-laboratory study he had directed following the recommendation of the 1997 NIH conference (see Carbone et al. (1997b) for meeting review of 1997 NIH conference) and upon the request of the International Mesothelioma Interest Group (IMIG).

 

Authors: George Klein, Amy Powers and Carlo Croce

0 Comments
A Novel Mechanism of Late Gene Silencing Drives SV40 Transformation of Human Mesothelial Cells

A Novel Mechanism of Late Gene Silencing Drives SV40 Transformation of Human Mesothelial Cells

Cancer Research, November 2008: Volume 68, Issue 22

Suppression of the late gene expression, usually by integration of the viral DNA into the host genome, is a critical step in DNA tumor virus carcinogenesis. SV40 induces high rates of transformation in infected primary human mesothelial cells in tissue culture, leading to the formation of immortal cell lines (SV40-transformed human mesothelial cell lines, S-HML).

0 Comments
Malignant Mesothelioma: Time to Translate?

Malignant Mesothelioma: Time to Translate?

Opinion: Lessons from the Clinic

Malignant Mesothelioma is a rare and poorly understood cancer with limited therapeutic approaches.

0 Comments
Consensus Report of the 2015 Weinman International Conference on Mesothelioma

Consensus Report of the 2015 Weinman International Conference on Mesothelioma

Special Article in the Journal of Thoracic Oncology, August 2016

On November 9 and 10, 2015, the International Conference on Mesothelioma in Populations Exposed to Naturally Occurring Asbestiform Fibers was held at the University of Hawaii Cancer Center in Honolulu, Hawaii. The meeting was cosponsored by the International Association for the Study of Lung Cancer, and the agenda was designed with significant input from staff at the U.S. National Cancer Institute and National Institute of Environmental Health Sciences.

A multidisciplinary group of participants presented updates reflecting a range of disciplinary perspectives, including mineralogy, geology, epidemiology, toxicology, biochemistry, molecular biology, genetics, public health, and clinical oncology. The group identified knowledge gaps that are barriers to preventing and treating malignant mesothelioma (MM) and the required next steps to address barriers.

This manuscript reports the group’s efforts and focus on strategies to limit risk to the population and reduce the incidence of MM. Four main topics were explored:

  1. Genetic risk
  2. Environmental exposure
  3. Biomarkers
  4. Clinical interventions

Authors: Michele Carbone, MD, PhD, Shreya Kanodia, PhD, Ann Chao, PhD, Aubrey Miller, MD, Anil Wali, PhD, David Weissman, MD, Alex Adjei, MD, PhD, Francine Baumann, PhD, Paolo Boffetta, MD, PhD, Brenda Buck, PhD, Marc de Perrot, MD, A. Umran Dogan, PhD, Steve Gavett, PhD, Alessandro Gualtieri, PhD, Raffit Hassan, MD, Mary Hesdorffer, NP, Fred R. Hirsch, MD, PhD, David Larson, PhD, Weimin Mao, PhD, Scott Masten, PhD, Harvey I. Pass, PhD, Julian Peto, DSc, Enrico Pira, Phd, Ian Steele, MD, Anne Tsao, MD, Gavitt Alida Woodard, MD, Haining Yang, PhD, Shakun Malik, MD

0 Comments
Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma

Differentiating between pleural malignant mesothelioma (MM) and lung cancer is often challenging. Immunohistochemical (IHC) stains used to distinguish these malignancies include markers  that are most often positive in malignant mesothelioma and less frequently positive in carcinomas, and vice versa. However, in 10 to 20% of the cases, the immunohistochemical staining results can be confusing and inconclusive,  and novel markers are sought to increase the diagnostic accuracy.

We stained 45 non-small cell lung cancers (32 adenocarcinomas and 13 squamous cell carcinomas) with a monoclonal antibody for BRCA1-associated protein 1 (BAP1) and also with an IHC panel we routinely use to help differentiate MM from carcinomas, which include calretinin, Wilms Tumor 1, cytokeratin 5, podoplantin D2-40, pankeratin CAM5.2, thyroid transcription factor 1, Napsin-A,  and p63.  Nuclear BAP1 expression was also analyzed in 35 MM biopsies. All 45 non-small cell lung cancer biopsies stained positive for nuclear BAP1, whereas 22/35 (63%)  MM biopsies lacked nuclear BAP1 staining, consistent with previous data. Lack of BAP1 nuclear staining was associated with MM. Focal BAP1 staining was observed in a subset of samples, suggesting polyclonality. Diagnostic accuracy of other classical IHC markers was in agreement with previous studies. Our study indicated that absence of nuclear BAP1 staining helps differentiate MM from lung carcinomas. We suggest that BAP1 staining should be added to the IHC panel that is currently used to distinguish these malignancies.  

 Authors: Michele Carbone, David Shimizu, Andrea Napolitano, Mika Tanji,  Harvey I. Pass, Haining Yang, Sandra Pastorino

0 Comments
RSS
123456